Gene Salkind, Director at Coeptis Therapeutics Holdings, Inc. (COEP), bought 11,600 shares at $0.69 ($8K) on 2024-01-05, disclosed to the SEC on 2024-01-09.
Open-market purchase of $8k COEP by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| UPXI | BUY | 2025-07-30 | $200K | — | Filing → |
| UPXI | BUY | 2025-04-25 | $1.1M | — | Filing → |
| COEP | BUY | 2023-08-30 | $30K | — | Filing → |